Repligen | RGEN - Sales Revenues


Repligen reported $189M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Agilent USD 1.86B 123M Sep/2025
Align Technology USD 1.05B 54.3M Dec/2025
Bio Techne USD 295.9M 9.34M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Bruker USD 860.5M 63.1M Sep/2025
Charles River Laboratories USD 1000M 32.14M Sep/2025
Danaher USD 6.84B 790M Dec/2025
Dentsply International USD 904M 32M Sep/2025
Exact Sciences USD 851M 39.9M Sep/2025
General Electric Aerospace USD 11.87B 560M Dec/2025
Henry Schein USD 3.34B 100M Sep/2025
Illumina USD 1.16B 80M Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Mettler Toledo International USD 1.13B 100M Dec/2025
Myriad Genetics USD 205.7M 7.4M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Repligen USD 189M 7M Sep/2025
Revvity USD 772.06M 73.06M Dec/2025
Standard Biotools USD 19.55M 2.21M Sep/2025
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Waters USD 800M 29M Sep/2025
West Pharmaceutical Services USD 804.6M 38.1M Sep/2025